[1]温娟娟,张景云,吕文韬,等.卡格列净对超重及肥胖2型糖尿病患者骨代谢指标的影响[J].国际内分泌代谢杂志,2024,44(01):5-8,25.[doi:10.3760/cma.j.cn121383-20221120-11054]
　Wen Juanjuan,Zhang Jingyun,Lyu Wentao,et al.Effect of SGLT-2 inhibitor on bone turnover markers in overweight and obese patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2024,44(01):5-8,25.[doi:10.3760/cma.j.cn121383-20221120-11054]
点击复制

卡格列净对超重及肥胖2型糖尿病患者骨代谢指标的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
44
期数:
2024年01期
页码:
5-8,25
栏目:
论著
出版日期:
2024-01-20

文章信息/Info

Title:
Effect of SGLT-2 inhibitor on bone turnover markers in overweight and obese patients with type 2 diabetes
作者:
温娟娟; 张景云; 吕文韬; 张秋梅
天津医科大学朱宪彝纪念医院、天津市内分泌研究所、国家卫生健康委员会激素与发育重点实验室、天津市代谢性疾病重点实验室,天津 300134
Author(s):
Wen Juanjuan;  Zhang Jingyun;  Lyu Wentao;  Zhang Qiumei
NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China
关键词:
2型糖尿病;  SGLT-2抑制剂;  骨代谢;  Ⅰ型胶原N端前肽;  Ⅰ型胶原C末端胶交联
Keywords:
Type 2 diabetes;  SGLT-2 inhibitor;  Bone metabolism;  PINP;  β-CTX
DOI:
10.3760/cma.j.cn121383-20221120-11054
摘要:
目的 观察钠-葡萄糖协同转运蛋白2抑制剂(SGLT-2i)卡格列净对超重及肥胖的2型糖尿病(T2DM)患者骨转换标志物的影响。方法 选取2019年10月9日至2020年12月28日住院的42例超重及肥胖T2DM患者,随机分为实验组(n=18)和对照组(n=24),实验组应用卡格列净联合其他类降糖药物,对照组应用非SGLT-2i类降糖药物,比较两组治疗前及治疗24周后血清Ⅰ型胶原N端前肽(PINP)及Ⅰ型胶原C末端肽交联(β-CTX)的变化。结果 治疗后两组比较,PINP无显著差异,实验组β-CTX水平低于对照组(P<0.05)。结论 应用卡格列净对超重及肥胖T2DM患者骨形成无明显影响,可能对骨吸收有一定抑制作用。
Abstract:
Objective To observe the effects of sodium-glucose cotransporter 2 inhibitor(SGLT-2i)Canagliflozin on bone turnover markers in overweight and obese patients with type 2 diabetes(T2DM).Methods A total of 42 overweight and obese T2DM patients(BMI≥25 kg/m2)who were hospitalized in our hospital from October 9, 2019, to December 28, 2020, were selected and randomly divided into experimental group(n=18)and control group(n=24). The experimental group was treated with Canagliflozin, while the control group was treated with non-SGLT-2 i. The changes of serum PINP and β-CTX levels were compared between the two groups before and after treatment for 24 weeks.Results After treatment, there was no significant difference in PINP between the two groups, while β-CTX was lower in the experimental group than that in the control group.Conclusions Canagliflozin has no significant effect on bone formation but may inhibit bone resorption in overweight and obese T2DM patients.

参考文献/References:

[1] Vilaca T,Schini M,Harnan S,et al.The risk of hip and nonvertebral fractures in type 1 and type 2 diabetes:a systematic review and meta-analysis update[J].Bone,2020,137:115457.DOI:10.1016/j.bone.2020.115457.
[2] Nielson CM,Srikanth P,Orwoll ES,et al.Obesity and fracture in men and women:an epidemiologic perspective[J].J Bone Miner Res,2012,27(1):1-10.DOI:10.1002/jbmr.1486.
[3] Taylor SI,Blau JE,Rother KI.Possible adverse effects of SGLT2 inhibitors on bone[J].Lancet Diabetes Endocrinol,2015,3(1):8-10.DOI:10.1016/S2213-8587(14)70227-X.
[4] 高丽华,朱亚军,张彩兰,等.利拉鲁肽对男性肥胖2型糖尿病患者骨代谢的影响[J].中国医师杂志,2018,20(11):1718-1720.DOI:10.3760/cma.j.issn.1008-1372.2018.11.030.
[5] Wang L,Li T,Liu J,et al.Association between glycosylated hemoglobin A1c and bone biochemical markers in type 2 diabetic postmenopausal women:a cross-sectional study[J].BMC Endocr Disord,2019,19(1):31.DOI:10.1186/s12902-019-0357-4.
[6] Liu XX,Jiang L,Liu Q,et al.Low bone turnover markers in young and middle-aged male patients with type 2 diabetes mellitus[J].J Diabetes Res,2020,2020:6191468.DOI:10.1155/2020/6191468.
[7] Rosenstock J,Aggarwal N,Polidori D,et al.Dose-ranging effects of canagliflozin,a sodium-glucose cotransporter 2 inhibitor,as add-on to metformin in subjects with type 2 diabetes[J].Diabetes Care,2012,35(6):1232-1238.DOI:10.2337/dc11-1926.
[8] Bays HE,Weinstein R,Law G,et al.Canagliflozin:effects in overweight and obese subjects without diabetes mellitus[J].Obesity(Silver Spring),2014,22(4):1042-1049.DOI:10.1002/oby.20663.
[9] Bilezikian JP,Watts NB,Usiskin K,et al.Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin[J].J Clin Endocrinol Metab,2016,101(1):44-51.DOI:10.1210/jc.2015-1860.
[10] Zibellini J,Seimon RV,Lee CM,et al.Does diet-induced weight loss lead to bone loss in overweight or obese adults?A systematic review and meta-analysis of clinical trials[J].J Bone Miner Res,2015,30(12):2168-2178.DOI:10.1002/jbmr.2564.
[11] De Jonghe S,Proctor J,Vinken P,et al.Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin[J].Chem Biol Interact,2014,224:1-12.DOI:10.1016/j.cbi.2014.09.018.
[12] Nauck MA,Del PS,Meier JJ,et al.Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin:a randomized,52-week,double-blind,active-controlled noninferiority trial[J].Diabetes Care,2011,34(9):2015-2022.DOI:10.2337/dc11-0606.

相似文献/References:

[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
　Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
　Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
　Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(01):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
　Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
　Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(01):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
　Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
　Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(01):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
　Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(01):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]

备注/Memo

备注/Memo:
基金项目:天津医科大学朱宪彝纪念医院科研基金(2019ZDKF03),天津市医学重点学科(专科)建设项目(TJYXZDXK-032A)
通信作者:张秋梅,Email:zxyzhangqiumei@126.com
更新日期/Last Update: 2024-03-20